Thomas Hanke studied Pharmacy at the Goethe University in Frankfurt. In 2014, he completed his PhD in the field of pharmaceutical chemistry, investigating the synthesis and pharmacological characterization of dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors as a new alternative strategy for anti-inflammatory drugs. In 2015, he joined Stefan Knapp´s group where he is working on the development of chemical probes for targeting kinases. For that, he is pursuing different strategies, including the synthesis of allosteric kinase inhibitors (e.g. for LIMK1/2) and the synthesis of macrocyclic compounds to generate new chemistry for targeting kinases.
Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Hartnett JR, Ingold MR, Zimmerman K, Machleidt T, Kirkland TA, Huwiler KG, Ohana RF, Slater M, Otto P, Cong M, Wells CI, Berger BT, Hanke T, Glas C, Ding K, Drewry DH, Huber KVM, Willson TM, Knapp S, Müller S, Meisenheimer PL, Fan F, Wood KV, Robers MB
Cell Chem Biol. 2017-11-13 . .doi: 10.1016/j.chembiol.2017.10.010
PMID: 29174542Kashima R, Redmond PL, Ghatpande P, Roy S, Kornberg TB, Hanke T, Knapp S, Lagna G, Hata A
Sci Signal. 2017-5-2 . 10(477): .doi: 10.1126/scisignal.aai8133
PMID: 28465421